We found that patients with T2DM treated with insulin have a significantly higher risk of 5-year incident HF compared with each of the 3 alternative treatments—GLP-1 RAs, DPP-4Is, and SGLT2Is. The gene discussed is INS; the disease is type 2 diabetes mellitus.